Dapivirine Ring

WHO Recommends the Dapivirine Vaginal Ring as a New Choice for HIV Prevention for Women at Substantial Risk of HIV Infection

Feb 04, 2021 | Julia Zigman

WHO recommended that the dapivirine vaginal ring (DPV-VR) may be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches.

The DPV-VR is a female-initiated option to reduce the risk of HIV infection. To properly use the ring, it must be worn inside the vagina for a period of 28 days, after which it should be replaced by a new ring. The ring is made of silicone and is easy to bend and insert. The ring works by releasing the antiretroviral drug dapivirine from the ring into the vagina slowly over 28 days.

Read more from the World Health Organization.


NACCHO logo small version02 square N pms321 Invert

About Julia Zigman

Pronouns: she/her

Julia Zigman is a Program Analyst on the NACCHO HIV, STI, & Viral Hepatitis team. Julia focuses primarily on NACCHO’s Ending the HIV Epidemic portfolio and is a lead staff member for the HIV, STI, and Viral Hepatitis Workgroup. Learn more about these programs here.

More posts by Julia Zigman

Related Posts

Monkeypox
  • Tools & Resources
  • Infectious Disease

National Monkeypox Vaccine Strategy: Phase One

This week the Biden Administration released the first phase of its national...

Jun 30, 2022 | Beth Hess

National Monkeypox Vaccine Strategy: Phase One

Prevent meningococcal disease
  • Infectious Disease

New Resources: 2022 Meningococcal Disease Outbreak...

The CDC and Florida Department of Health have released new resources and...

Jun 29, 2022 | Kimberly Nalley

New Resources: 2022 Meningococcal Disease Outbreak...

Harm reduction shutterstock 1063076657
  • HIV, STI, & Viral Hepatitis
  • Policy Statement
  • Substance Use Disorder

NACCHO Announces the Release of Updated Harm Reduction...

In its updated Harm Reduction policy statement, the National Association of...

Jun 28, 2022 | Anjana Rao

NACCHO Announces the Release of Updated Harm Reduction...

NACCHO color pms321
  • Press Release
  • Access to Care
  • Health Equity & Social Justice
  • Maternal, Child, & Adolescent Health

NACCHO Statement on U.S. Supreme Court Decision on Dobbs...

Today, the U.S. Supreme Court announced its decision on Dobbs v. Jackson...

Jun 24, 2022 | Adriane Casalotti

NACCHO Statement on U.S. Supreme Court Decision on Dobbs...

Cdc hiv nhtd 2022 promo english square
  • HIV, STI, & Viral Hepatitis

Dear Colleague: National HIV Testing Day

A new Dear Colleague letter from the CDC’s Division of HIV Prevention discusses...

Jun 24, 2022 | Guest Author, Julia Zigman

Dear Colleague: National HIV Testing Day

  • Tools & Resources
  • Climate Change
  • Health & Disability

Preparing People with Disabilities for Climate Change:...

Learn why having the voices of people with disabilities directly at the table...

Jun 23, 2022 | Guest Author

Preparing People with Disabilities for Climate Change:...

Under5 Guidance

COVID-19 Vaccine Authorized and Recommended for Children...

After successfully submitting data from their respective clinical trials, the...

Jun 21, 2022 | Amiris Roberson, Program Analyst, Immunization

COVID-19 Vaccine Authorized and Recommended for Children...

Cdc hiv nhtd 2022 promo english square
  • HIV, STI, & Viral Hepatitis

HIV Testing is Self-Care: National HIV Testing Day is...

Join health department, federal, and community partners across the U.S. in...

Jun 17, 2022 | Julia Zigman

HIV Testing is Self-Care: National HIV Testing Day is...

MRC Logo
  • Press Release

NACCHO Announces $9.5 Million in Awards to Local Medical...

Largest awards to date will strengthen MRC Network’s ability to deploy a ready,...

Jun 14, 2022 | Beth Hess

NACCHO Announces $9.5 Million in Awards to Local Medical...

Back to Top